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  The  purpose  of  this  study  was  to  evaluate  in  vitro t h e  
effects of hydrocortisone and aminophylline on adenosine 
diphosphate (ADP)-induced platelet aggregation in horses. 
Blood samples from 30 healthy Thoroughbred horses were 
collected  by  via  jugular  venipuncture  to  assess  platelet 
aggregation.  Platelet-rich  and  platelet-poor  plasma  were 
prepared from all samples by centrifugation and divided into 
three  different  aliquots.  In  the  first  aliquot,  platelet 
aggregation was measured after platelet activation with 1 μM 
and 0.5 μM ADP (Group A). In the other two aliquots, the 
effect  of  a  10  min  preincubation  with  hydrocortisone 
(Group B) or aminophylline (Group C) on ADP-induced 
aggregation at final ADP concentrations of 1 μM and 0.5 
μM  was  observed.  Platelet  aggregation,  recorded  by  an 
aggregometer, was evaluated by measuring the maximum 
degree of platelet aggregation and the initial velocities of 
platelet  aggregation  were  obtained.  Our  results  demon-
strated  the  inhibitory  effect  of  hydrocortisone  and  the 
induction effect of aminophylline on equine platelet responses 
in vitro. 
Keywords: adenosine diphosphate, aminophylline, horse, 
hydrocortisone, platelets
Introduction 
Platelet cohesion, more commonly referred as platelet 
aggregation, may be considered to be an indirect index of 
platelet functionality. The efficiency of platelet adhesion 
and aggregation at sites of vessel wall injury is dependent 
on the synergistic action of various adhesive and soluble 
agonist receptors, with the contribution of each individual 
receptor determined by prevailing blood flow conditions 
[15]. Blood platelets are a component of the haemostatic 
system in which the response to an agonist can be altered 
by compounds formed by or stored within platelets [9]. 
Platelets may become activated through different pathways 
including ones associated with collagen and von Wille-
brand factor exposed to the flowing blood following vessel 
wall injury, adenosine diphosphate (ADP) and adenosine 
triphosphate released from activated platelets, or thrombin 
[21]. A variety of substances are important mediators of 
haemostasis and thrombosis, and promote platelet aggre-
gation in vitro; these include ADP, adrenaline, collagen, and 
arachinodic acid [16,26]. The functions of these factors are 
commonly assessed by measuring platelet aggregation in 
vitro [36]. 
Evaluation of platelet response, or aggregation, to agonists 
in vitro is used to predict species-specific platelet responses 
in vivo [13,26,27]. In vitro platelet aggregation studies 
using ADP, collagene, arachidonic acid, and epinephrine 
have been performed in humans, camels, dogs, and calves 
[12,34]. Equine platelets aggregation in response to platelet 
activating factors and ADP has been well established [30]. 
Activation of platelets by ADP modifies the conformational 
state of receptor, enabling it to bind to the fibrinogen 
molecule and thus stimulating the aggregation cascade [11]. 
Platelet adhesion, aggregation, secretion, and survival 
change with atherosclerosis and thromboembolic pheno-
mena, thus further increasing interest in anti-aggregation 
drugs [38]. In fact, platelet function seems to be affected by 
many clinical conditions in equine medicine [23,24] and 
by a variety of drugs. However, only few studies have 
comparatively evaluated the effects of some [6,17,22,32]. 
A few authors have investigated the modulation of platelet 
function by some nonsteroidal anti-inflammatory drugs 
such as sulfazamet, phenylbutazone, acetylsalicylic, and 
indomethacin [6,22,25]. Equine platelet function was also 
examined in relation to glucocorticoid hormones; these 
studies showed that although glucocorticoids can increase 
the number of circulating platelets, neutrophils, and red 
blood cells, platelet aggregation is inhibited [7]. Other 
researchers limited themselves to studying pharmacokinetics 
and bioavailability of drugs, such theophilline and amino-216    Stefania Casella et al.
Table 1. Summary of haematological and clotting parameters of 
30 Thoroughbred horses with the corresponding reference values
Parameters Mean values* Reference
values [2,37]
Red blood cell (M/μL)     8.79 ± 0.80   8.7∼11.4 
White blood cell (K/μL)     6.83 ± 1.32   6.8∼11.1 
Haemoglobin (g/dL)   14.51 ± 1.33 14.1∼18.0 
Packed cell volume (%)   34.33 ± 8.02    32∼53 
Mean corpuscular    47.50 ± 2.40 39.6∼47.2 
 volume (fL)
Mean corpuscular    16.18 ± 0.90 14.7∼17.5 
 haemoglobin (pg)
Mean corpuscular    36.35 ± 1.20 35.8∼38.0 
 haemoglobin 
 concentration (g/dL)
Platelets (g/dL) 161.29 ± 25.35  120∼400 
Mean platelet volume (g/dL)     9.18 ± 1.04      6∼11 
Prothrombin time (sec)   12.65 ± 1.10    10∼14 
Activated partial    46.90 ± 3.03    25∼50 
thromboplastin time (sec)
Fibrinogen concentration  140.60 ± 10.12  100∼400 
 (mg/dL)
*Data are expressed as the means ± SD.
phylline, in horses [10,14] while the effects of some 
xanthine derivates on some hemostasis indices were only 
evaluated in humans [8,19]. In horses, the action of 
aminophylline on ADP-induced platelet aggregation has 
not been studied. Hydrocortisone is a main glucocorticoid 
hormone [1] and aminophylline is among the methylated 
xantines that serve as bronchodilators which are less potent 
and shorter-acting than theophylline [18]. Therefore, the 
aim of this study was to evaluate the in vitro effect of 
hydrocortisone and aminophylline on ADP-induced platelet 
aggregation in horses.
Materials and Methods
Thirty healthy Thoroughbreds (gelding, males and 
females), ranging in age from 8 to 10 years with mean body 
weight of 510 ± 50 kg, from the Horse Training Centre (La 
Pineta, Italy) were used for this study. Before the start of 
the study, all subjects underwent a heart exam, respiratory 
auscultations, and routine haematology and plasma bio-
chemistry tests while at rest. As shown in Table 1, the 
average values of hematological and clotting parameters 
obtained from the 30 healthy horses were within the 
normal physiological ranges [37]. The animals were 
routinely fed hay and a mixture of cereals (oats and barley) 
three times a day (08 : 00, 12 : 00, and 20 : 00) and had access 
to water ad libitum. The animal husbandry and experimen-
tation protocols were reviewed and approved in 
accordance with the standards recommended by the Guide 
for the Care and Use of Laboratory Animals and Directive 
86/609 European Economic Community.
Blood samples were collected from all horses via jugular 
venipuncture into 3.6 mL tubes containing 3.8% sodium 
citrate (1 part citrate: 9 parts blood) to assess platelet 
aggregation. From all blood samples, platelet-rich and 
platelet-poor plasma were collected by centrifugation and 
divided into three different aliquots. Platelet-rich plasma 
(PRP) was obtained by centrifuging the blood at 300 × g for 
20 min within 15 min of collection. The upper 2/3 of the 
PRP layer was carefully removed using a plastic transfer 
pipette and transferred into plastic laboratory containers.  
The remainder of the blood samples was centrifuged at 
3,000 × g for 10 min to obtain the platelet-poor plasma, 
which was also removed and transferred into plastic 
containers. 
Platelet aggregation in each sample was studied using a 
previously described method [28]. To the first aliquot (285 
μL) of PRP, 15 μL of ADP were added to evaluate 
ADP-induced platelet aggregation (Group A). To the other 
two aliquots (285 μL) of PRP, 15 μL of ADP and 15 μL of 
diluted hydrocortisone (Group B), or 15 μL of ADP and 10 
μL of diluted aminophylline (Group C) were added. 10 μL 
of hydrocortisone (Flebocortid Richter, 500 mg/5 mL; 
Sanofi-Aventis, Italy) were added to 4.99 mL of isotonic 
saline and 15 μL of this solution were added to 285 μL of 
PRP in order to obtain a final corticoid concentration of 10 
μL/mL, and 30 μL of aminophylline (Aminomal, 240 mg/10 
mL; Malesci, Italy) were added to 970 μL of 0.9% sodium 
chloride and 10 μL of this solution were added to 285 μL of 
PRP in order to obtain a final aminophylline concentration 
of 20 μg/mL. Using this protocol, the effect of a 10-min 
pre-incubation with hydrocortisone and with aminophylline 
on ADP-induced aggregation was determined. The final 
concentrations of the aggregating agent, ADP, were 1.0 and 
0.5 μM. Platelet aggregation was recorded for at least 4 min 
using an aggregometer (CLOT2; SEAC, Italy).
Platelet aggregation responses were evaluated according 
to two parameters: the maximum degree of aggregation 
and the initial velocity of aggregation. The maximum degree 
of aggregation, expressed as a percentage, was determined 
by measuring the maximum height of the aggregation 
wave over a 4-min period beginning at the onset of platelet 
aggregation. The initial velocity of aggregation was 
determined by drawing a line tangent to the steepest linear 
portion of the aggregation tracing, and determining the 
slope from one point along the curve. The slope of this 
tangent was expressed as percent per minute. 
All results were expressed as the mean ± SD, and showed 
the maximum degree of platelet aggregation along with the 
slope of platelet aggregation. All data were normally Hydrocortisone, aminophylline and platelet function in horse    217
Fig. 1. Average values of the maximum degree of platelet aggregation expressed as a percentage and the initial velocity of platelet 
aggregation expressed as the percentage per 1 min for samples from Group A (adenosine diphosphate [ADP]-induced platelet 
aggregation), Group B (ADP-induced platelet aggregation with hydrocortisone pre-incubation), and Group C (ADP-induced platelet 
aggregation with aminophylline pre-incubation). Values were measured in the presence of final ADP concentrations of 1 μM and 0.5 μM.
*vs. Group A (p < 0.05), • vs. Group B (p < 0.001).
distributed (p < 0.05, Kolmogorov-Smirnov’s test) and a 
one-way ANOVA was used to determine significant 
differences between all groups. A p  value < 0.05 was 
considered to be statistically significant. Bonferroni’s 
multiple comparison test was used for post hoc comparison. 
Data were analyzed using software (Statistica 7.5; 
StastSoft, USA). 
Results
Fig. 1 shows average values of the maximum degree of 
platelet aggregation and the slope of platelet aggregation 
expressed in with the conventional unit of measurement. 
Results of the one-way ANOVA showed statistically 
significant differences between the groups treated with 
hydrocortisone or aminophylline. At a final ADP concen-
tration of 1 μM, the maximum degree of aggregation and 
slope of aggregation were F2,89 = 25.56 (p < 0.0001) and 
F2,89 = 27.10 (p < 0.0001), respectively. At final a ADP 
concentration of 0.5 μM, the maximum degree of 
aggregation and the slope of aggregation were F2,89 = 11.61 
(p < 0.0001) and F2,89 = 15.92 (p < 0.0001), respectively. 
The mean maximum degree of platelet aggregation expressed 
as a percentage and the initial velocity of platelet aggregation 
expressed as a percentage per 1 min with final ADP 
concentrations of 1 μM and 0.5 μM are shown in Fig. 1. 
Discussion
The results from this study showed statistically significant 
differences for the maximum degree and slope of equine 
platelet aggregation between the samples pre-incubated 
with hydrocortisone or aminophylline. These findings 
demonstrated decreases in the parameters measured in our 
study following the addition of hydrocortisone. These 
values were increased after the addition of aminophylline.
Contrary to previous findings which showed that 
hydrocortisone does not affect major platelet receptors [31] 
and has no effect on prostaglandin synthesis in platelets 
[29,35], our research found that glucocorticoid inhibits 
platelet aggregation. Hydrocortisone probably affects the 
interaction of ADP with its receptors. Furthermore, the 
stimulation of phospholipase A2, activation of phospholipase 
C by tromboxane and platelet activating factor, formation 
of the second messengers inositol trisphosphate and 
diacylglycerol, and platelet degranulation (release of Ca
+2, 
ADP, and serotonin) may also be impacted since these 
stages are directly related to the structure and function of 
the platelet membrane [33]. Hydrocortisone seems to 
inhibit prostaglandin synthesis by intact cells and its effect 
seems to be caused by inhibition of phospholipase A2 that 
catalyzes the hydrolysis of arachidonic acid by membrane 
phospholipids [3]. Additionally, glucocorticoids inhibit 
vasodilatation that accompanies the synthesis of prostag-
landins by the vessel wall, normally associated with transient 
vasoconstriction, followed by vessel relaxation [20]. It has 
been demonstrated that the vessel relaxation after constric-
tion is promoted by prostaglandins released from the vessel 
wall in response to injury, and that the inhibition of 
prostaglandin synthesis leads to a sustained vasocon-
striction [3].
Unlike previous findings in which methyl xantines were 218    Stefania Casella et al.
found to markedly inhibit platelet aggregation [5], our results 
showed that methylxantine increased equine platelet aggre-
gation. Methylated xantines such as caffeine and theophyl-
line inhibit human platelet aggregation and are thought to 
inhibit platelet aggregation by promoting the accumulation 
of cyclic AMP in platelets through the inhibition of 
phosphodiesterase [5]. However, if we assume that the 
effects of methylxantines are secondary to the inhibition of 
phosphodiesterase activity, this may indicate that cyclic 
AMP plays a regulatory role in many important platelet 
functions. Moreover, it has been demonstrated that 
aminophylline does not affect the platelet release reaction 
[4]. These discrepancies may be due to differences in 
concentrations of aminophylline that were used for different 
studies or in species since most authors evaluated platelet 
aggregation after treatment with various concentrations of 
methylxantine in vitro [4].
In conclusion, the results of the present investigation 
showed the inhibitory effect of hydrocortisone on in vitro 
platelet aggregation in horses. We also demonstrated ability 
of aminophylline to promote the equine platelet response in 
vitro. Since compounds able to regulate platelet activities 
are essential in veterinary clinical practice, additional 
investigations using different hydrocortisone and amino-
phylline concentrations are necessary in order to further 
evaluate equine platelet aggregation.
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